Issue link: https://uberflip.scri.com/i/1521062
0529/24SCR019-14/R3 Abstract Presentation Calendar ASCO® 2024 16 Saturday Friday Sunday Monday Tuesday Publication Only MONDAY, JUNE 3 RD 1:30pm - 4:30pm Central Time (continued) Time Presentation Time Session Location Presentation Type Abstract Number Presentation Title 1st Author *SCRI First Author in Bold SCRI-Affiliated Coauthors Session Name 1:30 - 4:30pm Hall A Poster 8090 Updated results from a phase 1/2 study of HPN328, a tri-specific, half- life (T1/2) extended DLL3-targeting T-cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine cancers (NEC). Beltran H Johnson M Lung Cancer—Non- Small Cell Local- Regional/Small Cell/ Other Thoracic Cancers 1:30 - 4:30pm Hall A Poster 8585 Enfortumab vedotin (EV) in non- squamous and squamous non–small cell lung cancer (NSCLC) cohorts of EV-202. Muro K Gersten T Lung Cancer—Non- Small Cell Metastatic 1:30 - 4:30pm Hall A Poster 8047 Biomarker testing in early-stage NSCLC: Results from the MYLUNG Consortium. Evangelist M Evangelist M, Butrynski J, Paschold J, Ward P, Waterhouse D, Spira A, Ali K, Hakimian D, Jotte R, Larson T, Meshad M, Owera R, Richards D, Neubauer M, Robert N, Yori J, Pant M, Coleman R, Spigel D Lung Cancer—Non- Small Cell Local- Regional/Small Cell/ Other Thoracic Cancers 1:30 - 4:30pm Hall A Poster 8615 Clinical activity and safety of naptumomab estafenatox (NAP) and docetaxel in patients (pts) with checkpoint inhibitor (CPI) –pretreated advanced/metastatic non-small cell lung cancer (NSCLC): Preliminary results of a P2 trial. Larson T Jotte R, Abdelaziz A, Konduri K, Richards D, Meshad M, Nagaiah G, Spira A, Khandelwal P Lung Cancer—Non- Small Cell Metastatic 1:30 - 4:30pm Hall A Poster TPS8668 FURVENT: Phase 3 trial of furmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004). Spira A Spira A, Johnson M Lung Cancer - Non- Small Cell Metastatic 1:30 - 4:30pm Hall A Poster TPS8650 AFNT-211: A phase 1 study of autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V- specific, transgenic TCR, a CD8α/β coreceptor, and a FAS41BB switch receptor in patients with advanced/ metastatic solid tumors. Mitchell S Pelster M Lung Cancer—Non- Small Cell Metastatic 1:30 - 4:30pm Hall A Poster TPS8654 Beamion LUNG-2: A phase III randomized controlled trial of zongertinib (BI 1810631) versus standard of care (SoC) in patients with locally advanced/metastatic non- squamous non-small cell lung cancer (NSCLC) harboring HER2 tyrosine kinase domain (TKD) mutations Johnson M Johnson M Lung Cancer - Non- Small Cell Metastatic 1:30 - 4:30pm Hall A Poster TPS8652 eVOLVE-Lung02: A phase 3 study of first-line (1L) volrustomig plus chemotherapy (CT) versus pembrolizumab plus CT in metastatic non-small-cell lung cancer (mNSCLC) with PD-L1 tumor cell (TC) expression <50% Johnson M Johnson M Lung Cancer - Non- Small Cell Metastatic